Objectives: Advanced age is a well-known risk factor for cancer development. Although 12% of cancer is seen at the age of 65 and above worldwide, when the total cancer population is evaluated, 60% of them are age 65 and above. Our aim in our study is to share our follow-up and treatment experience with patients with very rare geriatric seminoma. Material and method: In our study, patients aged 65 and over who were diagnosed with seminoma between 07.09.1998-19.11.2018 in our center were evaluated retrospectively. Patient interview information, patient files and electronic system data were used for the study. Result: The data of 32 patients who were diagnosed with seminoma above 65 years of age were evaluated retrospectively. The median age of the patients is 68 (range 65-85). 24 (75%) patients stage 1; 6 (18.8%) patients are stage 2 and 2 (6.3%) patients are stage 3. As a first-line approach, active monitoring for 10 (31.3%) patients; Chemotherapy was applied to 22 patients. No patient RT was applied. The follow-up period of the study is 43 (range 2-121) months. Median PFS is 37 (range 1-115) months. The 5-year PFS value is 80.5%. During the follow-up period, 4 (13.5%) of the patients were ex. The Median OS value is 42 (range 2-121) months, and the 5-year OS value is 88%. The relationship between the stage and the OS is meaningful. Conclusion: According to the results of our study, elderly seminoma patients can be safely treated and cured. Since we encounter treatment-related mortality, modification may be needed in the treatment protocol and treatment doses according to the comorbidities of the patients.
Corresponding Author: Birol Yildiz